Current Part 2 topline outcomes reveal NS002’s potential for best-in-class epinephrine supply, with statistically important enhancements in early absorption in comparison with EpiPen®; pivotal research deliberate for This fall 2026
Firm advancing pipeline property NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic) towards first-in-human research anticipated to begin within the second half of 2026, considerably increasing the Firm’s intranasal product portfolio into extra excessive worth therapeutic areas
Firm properly funded via deliberate NS002 pivotal research and potential NDA submission
TEL AVIV, Israel, March 25, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical firm centered on the event of progressive intranasal merchandise, right this moment introduced the submitting of its annual report on Kind 20-F for the 12 months ended December 31, 2025, and supplied a enterprise replace highlighting latest Part 2 outcomes for NS002 and upcoming medical milestones.
Enterprise Replace
More Read
NS002 – Intranasal powder Epinephrine for Anaphylaxis
Accomplished Part 2 single and repeat dose medical research, with topline outcomes demonstrating statistically important enhancements in time to therapeutic threshold (T100) and a better proportion of members reaching therapeutic epinephrine ranges inside the first minutes following administration, in comparison with EpiPen®. The info additionally demonstrated NS002’s constant absorption throughout real-world circumstances, together with underneath a nasal allergic problem designed to simulate anaphylaxis situations. Advancing towards pivotal growth, with a pivotal medical research anticipated to provoke within the fourth quarter of 2026 and a deliberate readout within the first quarter of 2027, topic to regulatory alignment. The Firm believes the constructive Part 2 outcomes assist continued growth towards a possible NDA submission.
Early Pipeline
More Read
Nasus is advancing its earlier-stage pipeline applications, which leverage the Firm’s proprietary intranasal powder platform:
NS003 – Ondansetron for chemotherapy-induced nausea and vomitingNS004 – focusing on metabolic disordersNS005 – focusing on cardiovascular illnesses
All applications are at the moment in preclinical growth, with first-in-human Part 1 research anticipated to provoke within the second half of 2026 for NS003 and NS004, supporting the continued enlargement of the Firm’s intranasal product portfolio.
Monetary Outcomes
Analysis and Growth Bills: Analysis and growth bills had been $2.4 million for the 12 months ended December 31, 2025, in contrast with $0.3 million for the 12 months ended December 31, 2024. The rise was primarily attributable to bills paid in reference to the event of NS002.
Common and Administrative Bills: Common and administrative bills had been $2.7 million for the 12 months ended December 31, 2025, in contrast with $0.7 million for the 12 months ended December 31, 2024. The rise was primarily as a result of firm’s transition to a public firm.
More Read
Internet Loss: For the 12 months ended December 31, 2025, internet loss was $5.9 million in contrast with a internet lack of $1.5 million for the 12 months ended December 31, 2024. The full variety of shares excellent as of December 31, 2025 was 9,015,383.
About Nasus PharmaNasus Pharma is a clinical-stage pharmaceutical firm creating plenty of intranasal powder merchandise addressing acute medical circumstances locally. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free different to Epinephrine autoinjectors for sufferers with anaphylaxis. Intranasal administration is best suited for these conditions by which fast drug supply is required and provides needle-free, easy-to-use options. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) expertise is designed for fast and dependable drug supply, leveraging the nasal cavity’s wealthy vascular community for fast absorption. The PBI formulation makes use of uniform spherical powder particles for broad dispersion and doubtlessly sooner, increased absorption in comparison with liquid-based nasal merchandise. For additional details about the Firm, please go to www.nasuspharma.com or comply with on Twitter (X) or LinkedIn.
Ahead Trying StatementsThis press launch comprises “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act of 1995 and different U.S. federal securities legal guidelines. Phrases resembling “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the detrimental of those phrases, comparable expressions or variations of such phrases are supposed to determine forward-looking statements. For instance, Nasus Pharma is utilizing ahead trying statements on this press launch when it discusses: the timing and outcomes of deliberate medical research, together with the NS002 pivotal research, potential regulatory submissions, together with a possible NDA, the event and timing of pipeline applications, together with NS003, NS004 and NS005, anticipated medical and growth milestones, enlargement of the Firm’s product portfolio, and the Firm’s monetary place and anticipated money runway. Historic outcomes of scientific analysis and medical and preclinical trials don’t assure that the conclusions of future analysis or trials will recommend an identical and even comparable conclusions. Ahead-looking statements are primarily based on the Firm’s present expectations and are topic to uncertainties, dangers and assumptions which might be tough to foretell. Additional, sure forward-looking statements are primarily based on assumptions as to future occasions that will not show to be correct. These and different dangers and uncertainties are described extra absolutely within the part titled “Risk Factors” within the Firm’s Annual Report on Kind 20-F filed with the U.S. Securities and Trade Fee on March 25, 2026. Ahead-looking statements contained on this press launch are made as of this date, and the Firm undertakes no responsibility to replace such data besides as required underneath relevant legislation.
